Microbix Biosystems Inc., a company based in Mississauga, Ontario, has announced the upcoming release of its financial results for the third quarter of fiscal 2026. The results, which will cover the period ending June 30, 2026, are scheduled to be published before the market opens on August 13, 2026.
Following the release of the financial statements, management will hold a webinar discussion at 10:00 AM ET on the same day. This session will feature insights from key executives, including the CEO, CFO, and COO, who will discuss the company's performance and future outlook. Participants can join the webinar via audio with a specified webinar ID, and a recording will be available on Adelaide Capital's YouTube channel afterward.
Microbix Biosystems specializes in the creation of proprietary biological products aimed at enhancing human health. Its offerings primarily include vital components for the diagnostics sector, such as antigens for immunoassays and laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™). These products play a crucial role in clinical lab proficiency testing and the development and validation of various assays, ensuring the quality of diagnostic workflows.
In the last fiscal year (2025), Microbix reported revenues of CAD 18.6 million and has established a global presence with its QAPs available in over 30 countries.
As part of the announcement, Microbix cautioned that its financial performance and future actions may be influenced by several uncertainties. Factors such as production challenges, foreign sales, and financial stability could significantly impact the company’s operations. The management emphasizes that the forthcoming information includes forward-looking statements that are subject to change based on various circumstances beyond their control.
Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) plans to release its Q3 2026 financial results prior to the start of trading on August 13, 2026. This will include financial statements and management analysis.
The Q3 2026 results will be discussed in a webinar featuring Microbix's CEO, CFO, and COO at 10:00 AM ET on August 13, 2026.
Microbix focuses on creating proprietary biological products, particularly critical ingredients for the diagnostics industry, including antigens for immunoassays and products related to laboratory quality assessment (QAPs™) and reference materials (QUANTDx™).
Microbix Biosystems Inc. is ISO 9001 & 13485 certified, and is also registered with the U.S. FDA, Australian TGA, and licensed by Health Canada, in addition to providing IVDR-compliant CE marked products.
The company cautions that forward-looking information is inherently uncertain and may be affected by various material factors beyond their control, which could lead to actual performance differing from expectations.
Further information about Microbix's Q3 2026 results will be available in the financial statements and associated news release expected on August 13, 2026, and a replay of the results discussion will be available on Adelaide Capital’s YouTube channel.
In its last reported fiscal year (2025), Microbix Biosystems Inc. reported revenues of C$ 18.6 million.
Microbix's quality assessment products (QAPs) are currently available in over 30 countries, facilitated by a network of international distributors.